4-(1,8-Naphthyridin-2-yl)butanenitrile | 227938-79-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(1,8-Naphthyridin-2-yl)butanenitrile
• CAS: 227938-79-6
• 化学式: C₁₂H₁₁N₃
• 分子量: 197.239
• InChiKey: MLFRYEWCXWLMHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  49.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(1,8-Naphthyridin-2-yl)butanenitrile 在 palladium on activated charcoal 吡啶 、 硫化氢 、 氢气 、 三乙胺 作用下， 以 1,4-二氧六环 为溶剂， 生成 Ethyl 3-(6-methoxypyridin-3-yl)-4-[2-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,3-thiazol-4-yl]butanoate
  参考文献：
  名称：

  Synthesis of 2,5-thiazole butanoic acids as potent and selective αvβ3 integrin receptor antagonists with improved oral pharmacokinetic properties

  摘要：

  We describe a series of 2,5 thiazole containing compounds, which are potent antagonists of the integrin alpha(V)beta(3) and show selectivity relative to the other integrins, such as alpha(IIB)beta(3) and alpha(V)beta(6). These analogs were demonstrated to have high bioavailability relative to other relative heterocyclic analogs. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.017
• 作为产物：
  描述：

  2-氨基-3-吡啶甲醛 、 5-酮基已腈 在 L-脯氨酸 作用下， 以 乙醇 为溶剂， 生成 4-(1,8-Naphthyridin-2-yl)butanenitrile
  参考文献：
  名称：

  Synthesis of 2,5-thiazole butanoic acids as potent and selective αvβ3 integrin receptor antagonists with improved oral pharmacokinetic properties

  摘要：

  We describe a series of 2,5 thiazole containing compounds, which are potent antagonists of the integrin alpha(V)beta(3) and show selectivity relative to the other integrins, such as alpha(IIB)beta(3) and alpha(V)beta(6). These analogs were demonstrated to have high bioavailability relative to other relative heterocyclic analogs. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.017

文献信息

• Heteroarylakanoic acids as intergrin receptor antagonists
  申请人：——

  公开号：US20040092497A1

  公开（公告）日：2004-05-13

  The present invention relates to a class of compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of Formula (I), and methods of selectively antagonizing the &agr;&ngr;&bgr; 3 and/or the &agr;&ngr;&bgr; 5 integrin without significantly antagonizing the IIb/IIIa integrin. 1

  本发明涉及一类由式（I）表示的化合物或其药学上可接受的盐、包含式（I）化合物的制药组合物以及选择性拮抗&agr;&ngr;&bgr;3和/或&agr;&ngr;&bgr;5整合素而不显著拮抗IIb/IIIa整合素的方法。
• Heteroarylalkanoic acids as integrin receptor antagonists
  申请人：——

  公开号：US20020133023A1

  公开（公告）日：2002-09-19

  The present invention relates to a class of compounds represented by the Formula I 1 or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively antagonizing the &agr; V &bgr; 3 and/or the &agr; V &bgr; 5 integrin without significantly antagonizing the IIb/IIIa or &agr; V &bgr; 6 integrin.

  本发明涉及一类由式I1表示的化合物或其药学上可接受的盐，包括式I的药物组合物，并且涉及一种选择性拮抗&agr;V&bgr;3和/或&agr;V&bgr;5整合素而不显著拮抗IIb/IIIa或&agr;V&bgr;6整合素的方法。
• Integrin receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US06268378B1

  公开（公告）日：2001-07-31

  The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the vitronectin receptors &agr;v&bgr;3 and/or &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease, and tumor growth.

  本发明涉及化合物及其衍生物、它们的合成以及它们作为维腾联蛋白受体拮抗剂的用途。更具体地说，本发明的化合物是维腾联蛋白受体αvβ3和/或αvβ5的拮抗剂，可用于抑制骨吸收、治疗和预防骨质疏松症，并抑制血管再狭窄、糖尿病视网膜病变、黄斑变性、血管生成、动脉粥样硬化、炎症、病毒性疾病和肿瘤生长。
• Convergent, parallel synthesis of a series of β-substituted 1,2,4-oxadiazole butanoic acids as potent and selective αvβ3 receptor antagonists
  作者：Mark L. Boys、Lori A. Schretzman、Nizal S. Chandrakumar、Michael B. Tollefson、Scott B. Mohler、Victoria L. Downs、Thomas D. Penning、Mark A. Russell、John A. Wendt、Barbara B. Chen、Heather G. Stenmark、Hongwei Wu、Dale P. Spangler、Michael Clare、Bipin N. Desai、Ish K. Khanna、Maria N. Nguyen、Tiffany Duffin、V. Wayne Engleman、Mary Beth Finn、Sandra K. Freeman、Melanie L. Hanneke、Jeffery L. Keene、Jon A. Klover、G. Allen Nickols、Maureen A. Nickols、Christina N. Steininger、Marisa Westlin、William Westlin、Yi X. Yu、Yaping Wang、Christopher R. Dalton、Sarah A. Norring

  DOI：10.1016/j.bmcl.2005.11.008

  日期：2006.2

  We describe a series of 1,2,4-oxadiazoles, which are potent antagonists of the integrin alpha(V)beta(3) and, in addition, show selectivity relative to the other beta(3) integrin alpha(IIB)beta(3). In whole cells, the majority of these analogs also demonstrated modest selectivity against other alpha(V), integrins such as alpha(V)beta(1) and alpha(V)beta(6). (c) 2005 Elsevier Ltd. All rights reserved.
• US6268378B1
  申请人：——

  公开号：US6268378B1

  公开（公告）日：2001-07-31